Showing results (881-890 of 979) with videos related to

Sort By:
Pageof 98
Immunological Reviews|November 6, 2007
Ecto-calreticulin in immunogenic chemotherapyMichel Obeid, Antoine Tesniere, Theocharis Panaretakis, et al.
Dermatology and Therapy|September 26, 2025
Efficacy and Tolerability of a Facial Serum Before and After Ablative Fractional Carbon Dioxide Laser: A Randomized Controlled Trial on Chinese WomenJing Li, Xingzuo Liu, Zhiming Zhang, et al.
Mbio|February 29, 2024
Cooperation between two modes for DNA replication initiation in the archaeon <i>Thermococcus barophilus</i>Logan Mc Teer, Yann Moalic, Valérie Cueff-Gauchard, et al.
Blood|April 2, 2020
International prognostic indices in diffuse large B-cell lymphoma: a comparison of IPI, R-IPI, and NCCN-IPIAmy S Ruppert, Jesse G Dixon, Gilles Salles, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|November 19, 2021
Efficacy of Severe Acute Respiratory Syndrome Coronavirus-2 Vaccine in Patients With Thoracic Cancer: A Prospective Study Supporting a Third Dose in Patients With Minimal Serologic Response After Two Vaccine DosesValérie Gounant, Valentine Marie Ferré, Ghassen Soussi, et al.
Journal of Immunology (Baltimore, Md. : 1950)|February 7, 2004
Exosomes as potent cell-free peptide-based vaccine. I. Dendritic cell-derived exosomes transfer functional MHC class I/peptide complexes to dendritic cellsFabrice André, Nathalie Chaput, Nöel E C Schartz, et al.
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases|October 8, 2020
Follow-up of adults with noncritical COVID-19 two months after symptom onsetClaudia Carvalho-Schneider, Emeline Laurent, Adrien Lemaignen, et al.
Nature Communications|May 31, 2018
Induction of anergic or regulatory tumor-specific CD4<sup>+</sup> T cells in the tumor-draining lymph nodeRuby Alonso, Héloïse Flament, Sébastien Lemoine, et al.
Transfusion|September 1, 2005
Therapeutic efficacy and safety of photochemically treated apheresis platelets processed with an optimized integrated setKarin Janetzko, Jean-Pierre Cazenave, Harald Klüter, et al.
Oncoimmunology|March 26, 2013
Phase I clinical trial combining imatinib mesylate and IL-2 in refractory cancer patients: IL-2 interferes with the pharmacokinetics of imatinib mesylatePatricia Pautier, Clara Locher, Caroline Robert, et al.
Pageof 98